Alnylam Pharmaceuticals (ALNY) Quick Ratio: History & Chart

Alnylam Pharmaceuticals, Inc.(ALNY)

Biotechnology · Cambridge, MA

$237.10+0.54 (+0.23%)

At close: Aug 28, 2026, 4:00 PM ET

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies include givosiran, aimed at adolescent patients with AHP; patisiran, being explored for transthyretin amyloidosis (ATTR) with cardiomyopathy; cemdisiran for complement-mediated disorders; ALN-AAT02 for AAT deficiency-associated liver disease; ALN-HBV02 for chronic hepatitis B virus infection; Zilebesiran for hypertension; and ALN-HSD for non-alcoholic steatohepatitis (NASH). Additionally, other candidates such as Fitusiran for hemophilia and bleeding disorders, Inclisiran for hypercholesterolemia, an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran for ATTR amyloidosis (currently in Phase 3 clinical trials) are also progressing. Alnylam also engages in strategic alliances with other pharmaceutical leaders. Notable collaborations include those with Regeneron Pharmaceuticals, Inc., focused on discovering and developing RNAi therapeutics for ocular and CNS targets, and with Sanofi Genzyme for broader RNAi therapeutic development and commercialization efforts. Further licensing and partnership agreements are in place with entities such as Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. Established in 2002, Alnylam Pharmaceuticals maintains its corporate headquarters in Cambridge, Massachusetts.

Cambridge, MA

2,500 employees

www.alnylam.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Yvonne L. Greenstreet

View full financials

ALNY Quick Ratio (Acid-Test) Metrics

QUICK RATIO (ACID-TEST)

2.99

QUICK RATIO (ACID-TEST) AVG TTM

2.80

QUICK RATIO (ACID-TEST) AVG 3Y

2.88

QUICK RATIO (ACID-TEST) AVG 5Y

3.18

QUICK RATIO (ACID-TEST) AVG 10Y

4.66

QUICK RATIO (ACID-TEST) AVG 15Y

6.08

QUICK RATIO (ACID-TEST) AVG 20Y

5.65

CURRENT VS TTM AVG

+6.81%

CURRENT VS 3Y AVG

+3.72%

CURRENT VS 5Y AVG

-6.01%

CURRENT VS 10Y AVG

-35.84%

CURRENT VS 15Y AVG

-50.82%

CURRENT VS 20Y AVG

-47.03%

SECTOR MEDIAN · HEALTHCARE

1.26

median of 75 covered companies

CURRENT VS SECTOR MEDIAN

+137.34%

vs the sector median at left

NAME	MARKET CAP	QUICK RATIO (ACID-TEST)	TTM	3Y	5Y
Alnylam Pharmaceuticals, Inc. (ALNY)	$31.73B	2.99	2.80	2.88	3.18
Centene Corp. (CNC)vs ›	$31.99B	N/A	1.40	1.24	1.19
Biogen Inc. (BIIB)vs ›	$32.28B	1.26	1.46	1.69	1.64
GE HealthCare Technologies Inc. (GEHC)vs ›	$32.40B	0.72	0.86	0.82	0.76
Zoetis Inc. (ZTS)vs ›	$32.42B	1.84	1.51	1.66	1.96
Waters Corporation (WAT)vs ›	$31.02B	1.29	1.39	1.50	1.54
Medline Inc. (MDLN)vs ›	$29.83B	2.61	1.97	2.09	2.09
DexCom, Inc. (DXCM)vs ›	$34.27B	1.43	1.44	1.80	2.83
ResMed Inc. (RMD)vs ›	$34.86B	2.42	2.47	2.11	1.90
Alcon Inc. (ALC)vs ›	$35.12B	1.30	1.55	1.40	1.42

NAME

MARKET CAP

QUICK RATIO (ACID-TEST)

TTM

Alnylam Pharmaceuticals, Inc. (ALNY)

$31.73B

2.99

2.80

2.88

3.18

Centene Corp. (CNC)vs ›

$31.99B

N/A

1.40

1.24

1.19

Biogen Inc. (BIIB)vs ›

$32.28B

1.26

1.46

1.69

1.64

GE HealthCare Technologies Inc. (GEHC)vs ›

$32.40B

0.72

0.86

0.82

0.76

Zoetis Inc. (ZTS)vs ›

$32.42B

1.84

1.51

1.66

1.96

Waters Corporation (WAT)vs ›

$31.02B

1.29

1.39

1.50

1.54

Medline Inc. (MDLN)vs ›

$29.83B

2.61

1.97

2.09

DexCom, Inc. (DXCM)vs ›

$34.27B

1.43

1.44

1.80

2.83

ResMed Inc. (RMD)vs ›

$34.86B

2.42

2.47

2.11

1.90

Alcon Inc. (ALC)vs ›

$35.12B

1.30

1.55

1.40

1.42

Quick Ratio (Acid-Test) FAQ

What is the quick ratio (acid-test) for Alnylam Pharmaceuticals, Inc. (ALNY)?

The quick ratio (acid-test) for ALNY stock is 2.99.

Is Alnylam Pharmaceuticals, Inc.'s quick ratio (acid-test) high or low?

The quick ratio (acid-test) of 2.99 is in line with its 5-year average of 3.18, near the low end of its 5-year range (2.49–4.76).

What is the TTM average quick ratio (acid-test) for Alnylam Pharmaceuticals, Inc. (ALNY)?

The TTM average quick ratio (acid-test) for ALNY stock is 2.80.

What is the 3Y average quick ratio (acid-test) for Alnylam Pharmaceuticals, Inc. (ALNY)?

The 3Y average quick ratio (acid-test) for ALNY stock is 2.88.

What is the 5Y average quick ratio (acid-test) for Alnylam Pharmaceuticals, Inc. (ALNY)?

The 5Y average quick ratio (acid-test) for ALNY stock is 3.18.

What is the 10Y average quick ratio (acid-test) for Alnylam Pharmaceuticals, Inc. (ALNY)?

The 10Y average quick ratio (acid-test) for ALNY stock is 4.66.

What is the 15Y average quick ratio (acid-test) for Alnylam Pharmaceuticals, Inc. (ALNY)?

The 15Y average quick ratio (acid-test) for ALNY stock is 6.08.

What is the 20Y average quick ratio (acid-test) for Alnylam Pharmaceuticals, Inc. (ALNY)?

The 20Y average quick ratio (acid-test) for ALNY stock is 5.65.

DATE	QUICK RATIO (ACID-TEST)
2026-06-30	2.99
2026-03-31	3.06
2025-12-31	2.71
2025-09-30	2.49
2025-06-30	2.75
2025-03-31	2.98
2024-12-31	2.71
2024-09-30	2.69
2024-06-30	2.93
2024-03-31	3.07
2023-12-31	2.99
2023-09-30	3.04
2023-06-30	3.07
2023-03-31	3.58
2022-12-31	3.34
2022-09-30	3.33
2022-06-30	3.62
2022-03-31	4.14
2021-12-31	3.91
2021-09-30	4.22
2021-06-30	4.76
2021-03-31	3.83
2020-12-31	4.34
2020-09-30	4.14
2020-06-30	5.42
2020-03-31	4.48
2019-12-31	4.71
2019-09-30	5.22
2019-06-30	6.16
2019-03-31	9.12
2018-12-31	6.56
2018-09-30	10.95
2018-06-30	13.22
2018-03-31	14.61
2017-12-31	12.23
2017-09-30	9.83
2017-06-30	8.84
2017-03-31	6.23
2016-12-31	5.10
2016-09-30	9.14
2016-06-30	12.58
2016-03-31	15.82
2015-12-31	17.80
2015-09-30	18.24
2015-06-30	15.45
2015-03-31	13.51
2014-12-31	7.83
2014-09-30	11.31
2014-06-30	12.38
2014-03-31	8.04
2013-12-31	4.72
2013-09-30	3.63
2013-06-30	4.04
2013-03-31	4.83
2012-12-31	2.60
2012-09-30	8.37
2012-06-30	8.10
2012-03-31	3.13
2011-12-31	1.88
2011-09-30	3.71
2011-06-30	4.35
2011-03-31	4.94
2010-12-31	2.49
2010-09-30	2.46
2010-06-30	5.16
2010-03-31	2.77
2009-12-31	2.65
2009-09-30	2.26
2009-06-30	2.72
2009-03-31	4.02
2008-12-31	4.46
2008-09-30	4.43
2008-06-30	5.21
2008-03-31	5.36
2007-12-31	4.77
2007-09-30	5.46
2007-06-30	7.45
2007-03-31	8.93
2006-12-31	9.72
2006-09-30	5.89
2006-06-30	6.26
2006-03-31	6.86
2005-12-31	4.46
2005-09-30	3.34
2005-06-30	3.75
2005-03-31	6.75
2004-12-31	7.33
2004-09-30	7.11
2004-06-30	5.80
2004-03-31	2.76
2003-12-31	6.29
2003-09-30	0.00
2003-06-30	0.00
2003-03-31	0.00

DATE

QUICK RATIO (ACID-TEST)

2026-06-30

2.99

2026-03-31

3.06

2025-12-31

2.71

2025-09-30

2.49

2025-06-30

2.75

2025-03-31

2.98

2024-12-31

2.71

2024-09-30

2.69

2024-06-30

2.93

2024-03-31

3.07

2023-12-31

2.99

2023-09-30

3.04

2023-06-30

3.07

2023-03-31

3.58

2022-12-31

3.34

2022-09-30

3.33

2022-06-30

3.62

2022-03-31

4.14

2021-12-31

3.91

2021-09-30

4.22

2021-06-30

4.76

2021-03-31

3.83

2020-12-31

4.34

2020-09-30

4.14

2020-06-30

5.42

2020-03-31

4.48

2019-12-31

4.71

2019-09-30

5.22

2019-06-30

6.16

2019-03-31

9.12

2018-12-31

6.56

2018-09-30

10.95

2018-06-30

13.22

2018-03-31

14.61

2017-12-31

12.23

2017-09-30

9.83

2017-06-30

8.84

2017-03-31

6.23

2016-12-31

5.10

2016-09-30

9.14

2016-06-30

12.58

2016-03-31

15.82

2015-12-31

17.80

2015-09-30

18.24

2015-06-30

15.45

2015-03-31

13.51

2014-12-31

7.83

2014-09-30

11.31

2014-06-30

12.38

2014-03-31

8.04

2013-12-31

4.72

2013-09-30

3.63

2013-06-30

4.04

2013-03-31

4.83

2012-12-31

2.60

2012-09-30

8.37

2012-06-30

8.10

2012-03-31

3.13

2011-12-31

1.88

2011-09-30

3.71

2011-06-30

4.35

2011-03-31

4.94

2010-12-31

2.49

2010-09-30

2.46

2010-06-30

5.16

2010-03-31

2.77

2009-12-31

2.65

2009-09-30

2.26

2009-06-30

2.72

2009-03-31

4.02

2008-12-31

4.46

2008-09-30

4.43

2008-06-30

5.21

2008-03-31

5.36

2007-12-31

4.77

2007-09-30

5.46

2007-06-30

7.45

2007-03-31

8.93

2006-12-31

9.72

2006-09-30

5.89

2006-06-30

6.26

2006-03-31

6.86

2005-12-31

4.46

2005-09-30

3.34

2005-06-30

3.75

2005-03-31

6.75

2004-12-31

7.33

2004-09-30

7.11

2004-06-30

5.80

2004-03-31

2.76

2003-12-31

6.29

2003-09-30

0.00

2003-06-30

0.00

2003-03-31

0.00

Quick Ratio (Acid-Test): 2.99

ALNY Quick Ratio

ALNY Average Quick Ratio (Acid-Test) Chart

ALNY Current vs Average Quick Ratio (Acid-Test) Chart

ALNY Quick Ratio (Acid-Test) Metrics

ALNY Competitors' Quick Ratio (Acid-Test)

Liquidity Comparison

Quick Ratio (Acid-Test) Formula & Definition

Quick Ratio (Acid-Test) FAQ

ALNY Quick Ratio (Acid-Test) History

Related Metrics